Jyong Biotech shares surge 15.35% after-hours as clinical data for BOTRESO and MCS-8 presented at Urological Association of Asia Congress.

Jyong Biotech surged 15.35% in after-hours trading following the company’s presentation of clinical data for its Phase III drug BOTRESO and Phase II candidate MCS-8 at the 22nd Urological Association of Asia Congress. The event highlighted key validation for its urology pipeline, particularly BOTRESO, which targets benign prostatic hyperplasia (BPH), a growing global market. Additionally, the firm recently submitted a New Drug Application (NDA) for BOTRESO to the U.S. FDA, signaling regulatory progress toward commercialization. These developments, coupled with partnerships in Asia and a transition from a development-stage to market-ready biotech, likely drove investor optimism. The stock’s sharp rise aligns with the strategic milestones and potential market expansion, reinforcing confidence in the company’s pipeline and commercial prospects.